Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans

Neuromuscular Disorders

Volumn 14, Issue 6, 2004, Pages 365-370

  Gaud, Aurélie ^a   Simon, Jean Marc ^b   Witzel, Thomas ^b   Carre Pierrat, Maité ^a   Wermuth, Camille G ^b   Ségalat, Laurent ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

^b Prestwick Chemical Inc   (France)

Author keywords

Duchenne muscular dystrophy; Dystrophin; Nematode

Indexed keywords

DYSTROPHIN; PREDNISONE;

ARTICLE; CAENORHABDITIS ELEGANS; CELL COUNT; CELL DEGENERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; MODEL; MOLECULE; MUSCLE ATROPHY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SCREENING; SLOW MUSCLE;

EID: 2442560613     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2004.02.011     Document Type: Article

References (19)

1. Ahn A.H., Kunkel L.M. The structural and functional diversity of dystrophin. Nat Genet. 3:1993;283-291
2. Koenig M., Hoffman E.P., Bertelson C.J., Monaco A.P., Feener C., Kunkel L.M. Complete cloning of the Duchenne muscular dystrophy cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 50:1987;509-517
3. Dubowitz V. What is muscular dystrophy? Forty years of progressive ignorance. J R Coll Phys Lond. 34:2000;464-468
4. O'Brien K., Kunkel L. Dystrophin and muscular dystrophy: past, present, and future. Mol Genet Metab. 74:2001;75-88
5. Perkins K., Davies K. The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul Disord. 12:2002;S78-S89
6. Briguet A., Bleckmann D., Bettan M., Mermod N., Meier T. Transcriptional activation of the utrophin promoter B by a constitutively active Ets-transcription factor. Neuromuscul Disord. 13:2003;143-150
7. Wong B., Christopher C. Corticosteroids in Duchenne muscular dystrophy: a reappraisal. J Child Neurol. 17:2002;183-190
8. Bessou C., Giugia J.-B., Franks C.J., Holden-Dye L., Ségalat L. Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission. Neurogenetics. 2:1998;61-72
9. Roberts R.G., Bobrow M. Dystrophins in vertebrates and invertebrates. Hum Mol Genet. 7:1998;589-595
10. Gieseler K., Grisoni K., Ségalat L. Genetic suppression of phenotypes arising from mutations in dystrophin-related genes in Caenorhabditis elegans. Curr Biol. 10:2000;1092-1097
11. Moerman D., Fire A. Muscle: structure, function, development. Riddle D., Blumenthal T., Meyer B., Priess J. The nematode C. elegans II. 1997;417-470 Cold Spring Harbor Laboratory Press, Cold Spring Harbor
12. Mariol M.C., Segalat L. Muscular degeneration in the absence of dystrophin is a calciumdependent process. Curr Biol. 11:2001;1691-1694
13. Gieseler K., Grisoni K., Mariol M., Ségalat L. Overexpression of dystrobrevin delays locomotion defects and muscle degeneration in a dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord. 12:2002;371-377
14. Brenner S. The genetics of Caenorhabditis elegans. Genetics. 77:1974;71-94
15. Rand J., Johnston C. Genetic pharmacology: interactions between drugs and gene products. Epstein H., Shakes D. C. elegans: modern biological analysis of an organism. 1995;187-204 Academic Press, San Diego
16. Waterston R.H., Hirsh D., Lane T.R. Dominant mutations affecting muscle structure in Caenorhabditis elegans that map near the actin gene cluster. J Mol Biol. 180:1984;473-496
17. Grisoni K., Martin E., Gieseler K., Mariol M., Ségalat L. Genetic evidence for a dystrophinglycoprotein complex (DGC) in Caenorhabditis elegans. Gene. 294:2002;77-86
18. Metzinger L., Passaquin A., Leijendekker W., Poindron P., Ruegg U. Modulation by prednisolone of calcium handling in skeletal muscle cells. Br J Pharmacol. 116:1995;2811-2816
19. Passaquin A., Lhote P., Ruegg U. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol. 124:1998;1751-1759